<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621799</url>
  </required_header>
  <id_info>
    <org_study_id>Regen_006-0120</org_study_id>
    <nct_id>NCT04621799</nct_id>
  </id_info>
  <brief_title>Fibrin for Chronic Multi-level Discogenic Low Back Pain</brief_title>
  <official_title>A Prospective Registry Study Evaluating the Safety and Efficacy of Fibrin for Chronic Multi-level Discogenic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pauza, Kevin, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pauza, Kevin, MD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intra-annular injections of non-autologous fibrin for moderate to severe chronic low back&#xD;
      pain (LBP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to analyze data available in the PIs Regenerative Orthobiologics&#xD;
      Registry (ROR) and corresponding patient charts that will either support or refute the&#xD;
      efficacy of Intra-annular fibrin as treatment for moderate to severe low back pain.&#xD;
      Additionally, we seek to retrospectively identify possible predisposing factors that are&#xD;
      correlated with positive outcomes with respect to patient-reported pain and function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A prospective evaluation of a cohort of patients with a specific characteristic over time to see if they develop a particular endpoint or outcome based on a stated hypothesis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oswestry Disability Index (ODI)</measure>
    <time_frame>Two Years</time_frame>
    <description>The Oswestry Disability Index (ODI) is a questionnaire used by clinicians and researchers to quantify disability for low back pain. Scale for the ODI is from 0 (best) - 100 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numeric Rating Scale (NRS)</measure>
    <time_frame>Two Years</time_frame>
    <description>The NRS consists of a numeric version of the visual analog scale. It is labeled from zero to ten, with zero being an example of someone with no pain and ten being the worst pain possible. Scale for NRS is from 0 (best) - 10 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) for back pain</measure>
    <time_frame>Two Years</time_frame>
    <description>When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points. Scale for VAS for back pain is from 0 (best) - 10 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) for leg pain</measure>
    <time_frame>Two Years</time_frame>
    <description>When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points. Scale for VAS for leg pain is from 0 (best) - 10 (wors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Physical Health</measure>
    <time_frame>Two Years</time_frame>
    <description>The PROMIS Global-10 is a publicly available global health assessment tool that allows measurements of symptoms, functioning, and healthcare-related quality of life (HRQoL) for a wide variety of chronic diseases and conditions. Scale for PROMIS Physical Health is from 16.2 (worst) - 67.7 (best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Mental Health</measure>
    <time_frame>Two Years</time_frame>
    <description>The PROMIS Global-10 is a publicly available global health assessment tool that allows measurements of symptoms, functioning, and healthcare-related quality of life (HRQoL) for a wide variety of chronic diseases and conditions. Scale for PROMIS Mental Health is from 21.2 (worst) - 67.6 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>North American Spine Society (NASS) for patient satisfaction</measure>
    <time_frame>Two Years</time_frame>
    <description>The North American Spine Society (NASS) developed an outcome assessment instrument to measure diverse dimensions of the impact of lumbar spine problems. Scale range is from 1 to 4 (best to worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EURO Quality of Life (EuroQol)</measure>
    <time_frame>Two Years</time_frame>
    <description>EuroQol is an instrument which evaluates the generic quality of life developed in Europe and widely used. Scale is from 0.33 (worst - 0.88 (best).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Low Back Pain</condition>
  <condition>Disc Disease</condition>
  <condition>Disc Degeneration</condition>
  <condition>Radiculopathy</condition>
  <condition>Annular Disc Tear</condition>
  <arm_group>
    <arm_group_label>Fibrin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Non-Autologuos Fibrin (NAF) Subjects in the NAF arm received an injection of non-autologous fibrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrin sealant</intervention_name>
    <description>The intra-annular delivery of non-autologous fibrin into the annulus</description>
    <arm_group_label>Fibrin Group</arm_group_label>
    <other_name>Baxter Tisseel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient of Intra-annular fibrin injection for annular defects identified&#xD;
             radographically and by annulogram&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Scoliosis greater than 20 degrees&#xD;
&#xD;
          -  Spondylolysis&#xD;
&#xD;
          -  Spondylolisthesis greater than Grade 1&#xD;
&#xD;
          -  Disc extrusion&#xD;
&#xD;
          -  Disc herniations or bulges &gt; 4mm causing severe stenosis&#xD;
&#xD;
          -  Prior lumbar surgery or intradiscal procedure (i.e. intradiscal electrothermal&#xD;
             therapy, nucleoplasty)&#xD;
&#xD;
          -  Cauda equina syndrome&#xD;
&#xD;
          -  Active malignancy or tumor as source of symptoms&#xD;
&#xD;
          -  Evidence of prior lumbar vertebral body fracture or trauma&#xD;
&#xD;
          -  Foraminal stenosis at the affected levels resulting in severe thecal sac compression&#xD;
&#xD;
          -  Dynamic instability on lumbar flexion/extension radiographs&#xD;
&#xD;
          -  Positive response to diagnostic medial branch block or facet joint injection or&#xD;
             sacroiliac joint injection&#xD;
&#xD;
          -  Known bleeding disorder&#xD;
&#xD;
          -  Known or suspected hypersensitivity or allergy to drugs or components of the fibrin&#xD;
             sealant, including aprotinin, used in the procedure&#xD;
&#xD;
          -  Presence of ferromagnetic implants that would interfere with MRI evaluations&#xD;
&#xD;
          -  Active or pending workers' compensation claims or other litigation related to the&#xD;
             condition.&#xD;
&#xD;
          -  Pregnant or plans to become pregnant over the course of study participation (2 years)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Pauza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INTERVENTIONAL SPINE SPECIALIST</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Pauza, MD</last_name>
    <phone>239-317-3108</phone>
    <email>kevinpauza@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Wright</last_name>
    <phone>239-317-3108</phone>
    <email>carrie@drkevinpauza.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Interventional Spine Specialist</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Wright</last_name>
      <phone>903-941-9357</phone>
      <email>carrie@drkevinpauza.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-autologous fibrin</keyword>
  <keyword>Minimally Invasive</keyword>
  <keyword>Injections</keyword>
  <keyword>Intervertebral disc</keyword>
  <keyword>Annulus Fibrosus</keyword>
  <keyword>Sciatica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Radiculopathy</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

